Neither Breo Ellipta nor Breztri is the correct choice for asthma
You appear to be confusing medication names and indications—Breo Ellipta (fluticasone/vilanterol) is FDA-approved for asthma, but Breztri Aerosphere (budesonide/glycopyrrolate/formoterol) is NOT approved for asthma treatment. 1
Critical Clarification
Breztri Aerosphere is explicitly contraindicated for asthma. The FDA label clearly states: "BREZTRI AEROSPHERE is not for the treatment of asthma. It is not known if BREZTRI AEROSPHERE is safe and effective in people with asthma. BREZTRI AEROSPHERE contains formoterol fumarate. LABA medicines such as formoterol fumarate when used alone increase the risk of hospitalizations and death from asthma problems." 1
Breztri is a triple therapy (ICS/LAMA/LABA) designed exclusively for COPD, not asthma. The anticholinergic component (glycopyrrolate) has no established role in routine asthma management.
If You Meant Budesonide/Formoterol for Asthma
If your actual question is about budesonide/formoterol combinations (not Breztri), then:
For moderate-to-severe persistent asthma requiring step 3+ therapy, ICS/LABA combinations are the preferred treatment, with budesonide/formoterol being equivalent to other ICS/LABA options like fluticasone/salmeterol. 2, 3
Evidence-Based Approach:
Guidelines consistently recommend ICS/LABA combinations as preferred therapy for moderate-to-severe persistent asthma (step 3 and higher) in patients ≥12 years old 2, 4
Budesonide/formoterol is therapeutically equivalent to beclomethasone/formoterol in terms of efficacy and safety profile 5
The choice between specific ICS/LABA combinations (budesonide/formoterol vs. fluticasone/salmeterol vs. beclomethasone/formoterol) should be based on:
- Device preference and patient ability to use it correctly
- Dosing frequency (once vs. twice daily)
- Cost and insurance coverage
- Whether MART (maintenance and reliever therapy) approach is desired
Budesonide/Formoterol Advantages:
Can be used as MART (maintenance and reliever therapy), which significantly reduces exacerbations by 40% for mild exacerbations and 29% for severe exacerbations compared to fixed dosing 6
As-needed budesonide/formoterol reduces severe exacerbations by 54% compared to SABA alone in mild persistent asthma (RR=0.46) 7, 8
Lower total ICS exposure when used as-needed versus maintenance therapy while maintaining similar exacerbation rates 8
The Correct Answer for Your Question
Use Breo Ellipta (fluticasone/vilanterol) if you need an FDA-approved ICS/LABA for asthma. 9 However, budesonide/formoterol combinations (Symbicort) offer additional flexibility with MART dosing strategies that may provide superior exacerbation reduction 6, 10.
Never use Breztri Aerosphere for asthma—it is contraindicated. 1
Common Pitfall to Avoid:
Do not confuse COPD medications with asthma medications. Triple therapy (ICS/LAMA/LABA) like Breztri is for COPD only. Asthma treatment relies on ICS monotherapy or ICS/LABA combinations, with LABAs never used as monotherapy due to increased mortality risk 2, 4.